Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Acadia Pharmaceuticals
Thumbnail
April 26, 2022

Late-stage pain pipeline refuses to swell

Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.

Thumbnail
March 31, 2022

Vertex claims success with its fourth shot at acute pain

Article image
Vantage logo
February 01, 2022

Anavex Rett hit says nothing about blarcamesine’s effect size

Article image
Vantage logo
January 10, 2022

JP Morgan 2022 – day one sees healthy deal flow from biopharma

But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.

Article image
Vantage logo
December 07, 2021

Acadia breaks the Rett curse

Article image
Vantage logo
November 23, 2021

Neurocrine gets selective in schizophrenia

The group’s deal with Sosei will see it compete with Karuna and Cerevel.

Article image
Vantage logo
October 06, 2021

Biopharma’s stock market winners and losers so far this year

Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.

Article image
Vantage logo
September 28, 2021

Biotech’s key fourth-quarter data 

Deciphera, Allakos and Uniqure are all set for important data disclosures.

Article image
Vantage logo
August 09, 2021

US delay fells Axsome shares

Article image
Vantage logo
July 09, 2021

Alzheimer’s and Covid-19 developers make hay on the stock markets

Big risers include Eli Lilly, Biogen, Moderna and Biontech.

Article image
Vantage logo
July 07, 2021

Big pharma leads the way in stock market resurgence

And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.